IN OTHER NEWS

*USE OF GM-CSF BOOSTS IPILIMUMAB ACTIVITY! GO FIGURE THAT...
*NO SURPRISE HERE, CLASSIII BETA-TUBULIN PREDICT GOOD RESPONSE TO TAXANE IN ER NEGATIVE BREAST CANCER 
*MAKES PERFECT SENSE TO TINKLE WITH ANDROGEN RECEPTOR IN APOCRINE SUBTYPE OF CANCERS
*ONE GOOD NEGATIVE STUDY! OR IS IT? SEND COMMENTs!

Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma
American Journal of Clinical Oncology, 05/29/2013  Clinical Article

Govindarajan R et al. – The 28% progression-free survival rate at 27 weeks was not significantly higher than the recent historical control rate of 20% observed on the placebo arm of the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol trial (P=0.28). The combination of bevacizumab and erlotinib does not appear to have sufficient efficacy in patients with unresectable and metastatic HCC not amenable to local therapy.